BioSig Awarded U.S. Patent Claims for the Noise-Filtering Methods for its Signal Processing Technology
30 March 2021 - 11:30PM
- Claims address computer-implemented systems and
methods for filtering noise from input cardiac
signals using its PURE EP™ technology designed to elevate
treatments for cardiac arrhythmias
- Atrial fibrillation is the most common arrhythmia type,
affecting over 6 million people in the U.S. and causing more than
750,000 hospitalizations each year
- BioSig now has 34 issued or allowed worldwide patents
covering its advanced PURE
EP™ technology
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company commercializing an
innovative signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that the U.S. Patent Office had allowed a
utility patent covering its PURE EP™ noise-filtering
technology. The recently allowed patent application number
17/082,564 entitled “SYSTEMS AND METHODS FOR PERFORMING
ELECTROPHYSIOLOGY (EP) SIGNAL PROCESSING " was filed on October 28,
2020. The patent describes and claims systems and methods for
filtering noise (e.g., a cardiac signal) during a quiet period. In
particular, this patent involves filtering out harmonics and noise
from an input cardiac signal.
Conventional filtering techniques can alter signals and make it
difficult or impossible to see low-amplitude, high-frequency
signals inherent in cardiac monitoring and the visualization of
which signals could help treat cardiac arrhythmias, such as atrial
fibrillation and ventricular tachycardia.
One in 18 Americans suffers from cardiac arrhythmia. Atrial
fibrillation is the most common arrhythmia type, affecting over 33
million people worldwide, including over 6 million in the U.S. The
number of people suffering from atrial fibrillation is expected to
reach 8-12 million by 2050.1 According to the Centers for Disease
Control and Prevention (CDC), atrial fibrillation causes more than
750,000 hospitalizations in the U.S. each year, resulting in
approximately $6 billion in healthcare spending annually2.
In the adaptive filtering technology of the current patented
technology integrated into the PURE EP™, raw signals acquired by an
acquisition module are filtered and processed in accompanying
software using a digital processing module, with minimal use of
filters in the hardware. From a clinical perspective, the
patented PURE EP™ System can significantly assist a medical
team's decision making for patients undergoing various medical
therapies (such as ablation), with benefits including, but not
limited to: suppression of RF energy for cleaner, more reliable
recordings of intracardiac signals, less wander, and noise
reduction; improved dynamic range for better visualization,
especially of very low amplitude signals temporally situated within
large-amplitude signals; real-time digital processing and recording
of raw signals to facilitate signal filtering without affecting
original information and to reduce artifacts and noise.
The allowed patent application complements BioSig’s expanding
patent portfolio, which now includes 34 issued or allowed worldwide
patents. In addition, BioSig has exclusive licenses to 16
additional worldwide utility patent applications from the Mayo
Foundation for Medical Education and Research, three of which have
been issued and/or have been allowed to date. These 16 applications
are generally directed to electroporation and stimulation.
"We are pleased to announce this newest patent allowance which
demonstrates the clinical significance of our PURE EP™ System
in filtering noise from complex cardiac signals in the
electrophysiological setting,” commented Kenneth L. Londoner,
Chairman and CEO of BioSig Technologies, Inc. “The industry
reports consistently indicate that inability to detect small
intracardiac signals and difficulties to record high-quality
signals account for some of the main factors that interfere with
effective cardiac ablations. We believe that we have the leading
patent-protected solution for ensuring signal clarity that is
paramount to the success of cardiac ablations for all types of
cardiac arrhythmias.”
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve
signal fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP™ System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording, and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
1 Top 10 Things You should Know About Heart Rhythm; Scripps
Health.
2 Managing Atrial Fibrillation; Lisa Eramom MA, Medical
Economics Journal, February 25, 2019, Volume 96, Issue 4
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2024 to May 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From May 2023 to May 2024